ORP-101治疗腹泻型肠易激综合征的II期随机对照试验
这项II期随机双盲安慰剂对照试验纳入320例腹泻型肠易激综合征(IBS-D)患者,评估ORP-101(50mg、100mg)每日一次治疗12周的疗效与安全性。主要终点应答率在ORP-101 100mg组为28.3%,安慰剂组为21.9%,差异无统计学意义(P=.12);但多个次要和探索性终点支持ORP-101 100mg优于安慰剂,且耐受性良好。
要点
- ORP-101 100mg主要终点未达统计学显著,应答率28.3% vs 安慰剂21.9%(P=.12)。
- 多个次要和探索性终点支持ORP-101 100mg优于安慰剂。
- ORP-101耐受性良好,包括无胆囊者。
核心结论
- ORP-101 100mg在主要复合终点上未显著优于安慰剂,但在多个关键次要终点上显示更高应答。
研究设计与样本
- 随机、双盲、适应性设计、安慰剂对照的II期试验,纳入320例IBS-D患者。
- 患者随机接受ORP-101 50mg(n=65)、100mg(n=127)或安慰剂(n=128)每日一次治疗12周。
- 50mg剂量在期中分析后终止。
主要发现
- 主要终点应答率:ORP-101 50mg组16.9%,100mg组28.3%,安慰剂组21.9%(三组P=.79;100mg vs 安慰剂P=.12)。
- 次要和探索性终点在多个指标上支持ORP-101 100mg优于安慰剂。
- ORP-101耐受性良好,包括无胆囊者。
关键数值与推荐
- 主要终点为12周治疗期内至少50%的天数同时满足腹痛改善(较基线改善30%)和粪便稠度改善(布里斯托粪便量表平均每日稠度<5,或无排便时腹痛改善30%)。
临床怎么用
- ORP-101 100mg在IBS-D中显示一定疗效信号但主要终点未达显著,需进一步研究确认。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Safe and effective treatment for irritable bowel syndrome with diarrhea (IBS-D) is needed. ORP-101 is a novel partial μ receptor agonist and full κ receptor antagonist designed to act peripherally without central nervous system exposure. This study evaluated the efficacy and safety of ORP-101 in IBS-D. METHODS: In this randomized, double-blind, adaptive design placebo-controlled trial, eligible participants were randomized to receive ORP-101 50 mg, 100 mg, or placebo once daily for 12 weeks. As part of the adaptive design, the 50 mg ORP-101 dose was discontinued after interim analysis. The primary endpoint was composite response status of improvement in abdominal pain (improvement of 30% from baseline) and stool consistency (average daily stool consistency <5 on the Bristol Stool Form Scale, or 30% improvement in abdominal pain if no bowel movement) for 50% of days over 12-week treatment period. RESULTS: A total of 320 participants with IBS-D were randomized to ORP-101 50 mg (n = 65), 100 mg (n = 127), or placebo (n = 128). The proportion of primary endpoint responders for ORP-101 50 mg, 100 mg, and placebo participants was 16.9%, 28.3%, and 21.9%, respectively (P = .79 for the 3 groups and P = .12 for ORP-101 100 mg vs placebo). Secondary and exploratory endpoints favored ORP-101 100 mg vs placebo across multiple endpoints. ORP-101 was well-tolerated, including in those without gallbladders. CONCLUSIONS: In this phase II trial, ORP-101 100 mg did not achieve a statistically significant difference vs placebo for the primary endpoint; however, it showed higher response across multiple key endpoints. Future studies will study ORP-101 in other chronic pain conditions. CLINICALTRIALS: gov, Number: NCT04129619.
引用
- Singh P, Nee JW, Ballou S, et al. ORP-101 in Irritable Bowel Syndrome With Diarrhea: A Phase II Randomized, Controlled Trial. Clin Gastroenterol Hepatol. 2026. PMID: 41887552. doi:10.1016/j.cgh.2026.03.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。